Trademarkia Logo

Canada

C$
Trademark Search in Canada
MIRTH CAPSYLLS

View On IC.GC.CA

MIRTH CAPSYLLS
REGISTERED

on 19 Feb 2020

Last Applicant/ Owned by

ETHAN S. ERNEST

2850 SW Cedar Hills Blvd #425Beaverton, OR 97005

US

Serial Number

1865110 filed on 30th Oct 2017

Registration Number

TMA1072984 registered on 19th Feb 2020

Registration expiry Date

19th Feb 2030

Correspondent Address

GOODMANS LLP

ATTN: INTELLECTUAL PROPERTY GROUPBAY ADELAIDE CENTRE333 BAY STREET, SUITE 3400TORONTO

ONTARIO

CA

M5H2S7

MIRTH CAPSYLLS

Trademark usage description

medical marijuana and medical cannabis, and marijuana and cannabis in the form of pills, capsules, sublingual doses, mucous membrane doses, and edible Read More

Classification Information

Class [005]
Medical marijuana and medical cannabis, and marijuana and cannabis in the form of pills, capsules, sublingual doses, mucous membrane doses, and edibles namely gummies and chewing gum all for the relief of pain and treatment in palliative care, for reducing stress and fatigue, for mood enhancement, for relief from nausea, vomiting, headaches, muscle spasms, seizures, wasting syndrome and loss of appetite in AIDS and cancer patients, for maintaining general health and well-being, for treating symptoms associated with anorexia nervosa, Crohn's disease, multiple sclerosis, amyotrophic lateral sclerosis, fibromyalgia, spinal cord injury, epilepsy, migraines, arthritides and musculoskeletal disorders, neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, rheumatism, myasthenia gravis, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, convulsant and movement disorders, cervical dystonia, Meige's syndrome, glaucoma, asthma, hypertension, mental illness, namely anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, attention and hyperactivity disorders, Alzheimer's disease, and dementia, for the treatment of, and symptoms associated with, skin infections and irritations, namely bacterial skin infections, dermatitis, atrophie blanche, eczema, burns, rashes from skin allergies and reactions, psoriasis, pruritis and neuropathic pain, for the treatment of, and relief of symptoms associated with, inflammatory diseases, namely inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, and inflammatory bowel diseases, diseases of the liver, Wilson's disease, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis, osteoarthritis, and osteoporosis, and all the aforementioned products as anti-inflammatories, anti-viral enzyme activators, analgesics, sedatives, appetite stimulants and anti-emetics, anti-nauseants, intraocular pressure reducers, anti-tumors, antioxidants, antibacterials, antidepressants and antihypertensives

Classification kind code

11

Class [035]
Sale of marijuana and cannabis in the form of pills, capsules, sublingual doses, mucous membrane doses, and edibles namely gummies and chewing gum; business management, business administration, wholesale services and retail services, all of the foregoing relating to the retail, wholesale and online sales of marijuana and cannabis products

Classification kind code

11

Class [040]
Manufacture of marijuana and cannabis in the form of pills, capsules, sublingual doses, mucous membrane doses, and edibles namely gummies and chewing gum

Classification kind code

11

Class [044]
Operation of a website providing information about the health benefits of marijuana and cannabis

Classification kind code

11

Mark Details

Serial Number

1865110

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 190
on 18th Dec 2019		Registration Pending
Submitted for opposition 191
on 18th Dec 2019		Registration Fee Notice Sent
Submitted for opposition 42
on 24th Jul 2019		Advertised
Submitted for opposition 26
on 4th Jul 2019		Approved
Submitted for opposition 27
on 15th May 2019		Approval Notice Sent
Submitted for opposition 22
on 3rd Dec 2018		Search Recorded
Submitted for opposition 20
on 3rd Dec 2018		Examiner's First Report
Submitted for opposition 31
on 31st Oct 2017		Formalized
Submitted for opposition 30
on 30th Oct 2017		Filed
Submitted for opposition 1
on 30th Oct 2017		Created